可溶性尿激酶纤溶酶原激活物受体与狼疮肾炎肾内慢性化特征相关
该研究在23例狼疮肾炎患者中检测血清suPAR水平,发现活动期LN患者suPAR高于健康对照,治疗12个月后下降但仍高于对照;基线suPAR与基线及12个月慢性化指数相关,并可预测治疗后肾小球硬化及肾小管萎缩。
要点
- 活动性狼疮肾炎患者血清suPAR水平显著高于健康对照。
- 基线suPAR与肾内慢性化指数及间质纤维化相关。
- 基线suPAR可预测12个月肾小球硬化与肾小管萎缩。
核心结论
- 血清suPAR在活动性狼疮肾炎中升高,治疗12个月后下降但仍高于健康对照。
- suPAR水平与肾内慢性化特征相关,并可预测治疗后肾小球硬化与肾小管萎缩,提示其可能作为狼疮肾炎肾损伤的生物标志物。
研究设计与样本
- 研究纳入23例狼疮肾炎患者(其中19例为初发)和15例年龄性别匹配的健康对照。
- 在免疫抑制治疗开始前及12个月后检测血清suPAR水平(ELISA法),并与NIH活动性指数和慢性化指数进行Spearman秩相关分析。
主要发现
- 活动性LN患者suPAR水平为5.37±0.93 ng/mL,高于健康对照的2.64±0.97 ng/mL(p<0.001)。
- 治疗12个月后suPAR降至3.77±0.94 ng/mL(与基线比p=0.005),但仍高于健康对照(p<0.001)。
- 基线suPAR与基线慢性化指数相关(rho=0.541;p=0.008),与12个月慢性化指数相关(rho=0.554;p=0.017)。
- 基线suPAR与基线间质纤维化相关(rho=0.422;p=0.044),并预测12个月肾小球硬化(rho=0.580;p=0.011)和肾小管萎缩(rho=0.477;p=0.045)。
- 12个月suPAR与12个月活动性指数相关(rho=0.595;p=0.007),与12个月肾小球硬化相关(rho=0.572;p=0.013)。
临床怎么用
- 血清suPAR或可作为评估狼疮肾炎肾内慢性化损伤及预测治疗后肾小球硬化、肾小管萎缩的候选生物标志物。
局限性
- 样本量较小(23例患者,15例对照),结果需在更大队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Soluble urokinase plasminogen activator receptor (suPAR) is linked to organ damage in systemic lupus erythematosus (SLE). We investigated whether serum suPAR associates with histological activity and chronicity in diagnostic and 12-month repeat kidney biopsies in lupus nephritis (LN). METHODS: suPAR levels were determined using ELISA in serum samples from 23 LN patients (19 incident) before and 12 months after initiation of immunosuppressive therapy, and from 15 age- and sex-matched healthy controls. Correlations with NIH activity index (AI) and chronicity index (CI) scores were assessed using Spearman's rank correlation coefficient. RESULTS: suPAR levels were higher at active LN than in controls (5.37±0.93 ng/mL versus 2.64±0.97 ng/mL; p<0.001), decreased by month 12 (3.77±0.94 ng/mL; p=0.005), but remained elevated compared with controls (p<0.001). Baseline suPAR did not correlate with AI at baseline (rho=0.202; p=0.368) or month 12 (rho=0.332; p=0.165), whereas month-12 suPAR correlated with month-12 AI (rho=0.595; p=0.007). Baseline suPAR correlated with CI at baseline (rho=0.541; p=0.008) and month 12 (rho=0.554; p=0.017). Month-12 suPAR showed a trend towards a correlation with month-12 CI (rho=0.440; p=0.066). Baseline suPAR correlated with baseline interstitial fibrosis (rho=0.422; p=0.044) and predicted month-12 glomerular sclerosis (rho=0.580; p=0.011) and tubular atrophy (rho=0.477; p=0.045). Month-12 suPAR correlated with month-12 glomerular sclerosis (rho=0.572; p=0.013). CONCLUSIONS: Serum suPAR levels were elevated in active LN and, despite a decline, after 12 months of treatment compared with healthy individuals. suPAR levels correlated with intrarenal chronicity and predicted post-treatment glomerular sclerosis and tubular atrophy, suggesting suPAR as a potential biomarker of kidney damage in LN.
引用
- Jägerback S, Houssiau FA, Nikolopoulos D, et al. Soluble urokinase plasminogen activator receptor (suPAR) is associated with intrarenal chronicity features on diagnostic and repeat kidney biopsies in lupus nephritis. Semin Arthritis Rheum. 2026. PMID: 42365762. doi:10.1016/j.semarthrit.2026.153031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。